Connect Biopharma presented clinical and preclinical data supporting rademikibart at the American Thoracic Society (ATS) 2025 International Conference. The data highlighted rademikibart’s potential as a best-in-class treatment for patients with asthma or COPD experiencing an acute exacerbation.
New analyses from the previously completed Phase 2b study demonstrated rademikibart’s rapid onset of action and significant improvement in lung function, as measured by FEV1, within a day. The data also showed a reduction in acute exacerbations in patients with inflammation-mediated chronic asthma.
New preclinical data presented at the conference highlighted the differentiated structural and molecular dynamics of rademikibart, showing enhanced interleukin-4 receptor alpha (IL-4Rα) inhibition compared to dupilumab. This provides a molecular basis for the differentiated efficacy and safety observed with rademikibart.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.